These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11926386)

  • 1. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?
    Nitzsche EU; Hoegerle S; Mix M; Brink I; Otte A; Moser E; Imdahl A
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):237-42. PubMed ID: 11926386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
    Friess H; Langhans J; Ebert M; Beger HG; Stollfuss J; Reske SN; Büchler MW
    Gut; 1995 May; 36(5):771-7. PubMed ID: 7797130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
    Zimny M; Schumpelick V
    Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
    Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
    World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Fujimoto K; Doi R; Imamura M; Konishi J
    Ann Nucl Med; 2003 Jun; 17(4):261-79. PubMed ID: 12932109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography.
    Ozaki Y; Oguchi K; Hamano H; Arakura N; Muraki T; Kiyosawa K; Momose M; Kadoya M; Miyata K; Aizawa T; Kawa S
    J Gastroenterol; 2008; 43(2):144-51. PubMed ID: 18306988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified dual time point FDG-PET/computed tomography for determining dignity of pancreatic lesions.
    Bieg C; Mongelli F; Peterli R; Chirindel AF; Metzger J; von Flüe M; Gass M
    Nucl Med Commun; 2020 Jul; 41(7):682-687. PubMed ID: 32404649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
    J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.
    van Kouwen MC; Jansen JB; van Goor H; de Castro S; Oyen WJ; Drenth JP
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):399-404. PubMed ID: 15549297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET evaluation of indeterminate pancreatic masses.
    Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
    J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
    Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
    Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.